Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 404

1.

More on Causal Inference Studies.

Lederer DJ, Bell SC, Smyth AR, Chalmers JD.

Ann Am Thorac Soc. 2019 Feb 11. doi: 10.1513/AnnalsATS.201901-070LE. [Epub ahead of print] No abstract available.

PMID:
30742489
2.

Abolition of Pseudomonas aeruginosa AUST-01 from an Australian CF center: Do other strains remain?

Kidd TJ, Grimwood K, Bell SC.

Pediatr Pulmonol. 2019 Feb 11. doi: 10.1002/ppul.24258. [Epub ahead of print] No abstract available.

PMID:
30741479
3.

Infection risks for patients from healthcare workers with cystic fibrosis - Reply.

Bell SC, Stuart RL.

Respirology. 2019 Feb 4. doi: 10.1111/resp.13489. [Epub ahead of print] No abstract available.

PMID:
30716794
4.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group.

J Cyst Fibros. 2019 Jan 30. pii: S1569-1993(19)30014-1. doi: 10.1016/j.jcf.2019.01.008. [Epub ahead of print]

PMID:
30709744
5.

JCF - progress in 2018.

Bell SC, Castellani C, Flume PA.

J Cyst Fibros. 2019 Jan;18(1):1-5. doi: 10.1016/j.jcf.2018.12.008. No abstract available.

PMID:
30665544
6.

Correction: Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis.

Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson SA, Bell SC.

PLoS One. 2019 Jan 14;14(1):e0210929. doi: 10.1371/journal.pone.0210929. eCollection 2019.

7.

Multi-Centre Ethics and Research Governance Review Can Impede Non-Interventional Clinical Research.

Duplancic C, Crough T, Bell SC; Australian NTM in CF Study Group.

Intern Med J. 2018 Nov 12. doi: 10.1111/imj.14158. [Epub ahead of print]

PMID:
30417974
8.

Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis.

Smith DJ, Klein K, Hartel G, Wainwright CE, Bell SC, Anderson GJ, Reid DW.

Gene. 2019 Jan 30;683:12-17. doi: 10.1016/j.gene.2018.10.002. Epub 2018 Oct 3.

PMID:
30291871
9.

Antimicrobial resistance in cystic fibrosis: Does it matter?

Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):687-689. doi: 10.1016/j.jcf.2018.08.015. Epub 2018 Sep 27. No abstract available.

PMID:
30270113
10.

Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment.

Nagy B Jr, Bene Z, Fejes Z, Heltshe SL, Reid D, Ronan NJ, McCarthy Y, Smith D, Nagy A, Joseloff E, Balla G, Kappelmayer J, Macek M Jr, Bell SC, Plant BJ, Amaral MD, Balogh I.

J Cyst Fibros. 2018 Sep 26. pii: S1569-1993(18)30795-1. doi: 10.1016/j.jcf.2018.08.013. [Epub ahead of print]

PMID:
30268371
11.

Defining antimicrobial resistance in cystic fibrosis.

Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):696-704. doi: 10.1016/j.jcf.2018.08.014. Epub 2018 Sep 25. Review.

PMID:
30266518
12.

Reply to: Use of Masks in Cystic Fibrosis Patients.

Wood ME, Stockwell RE, Bell SC.

Am J Respir Crit Care Med. 2018 Sep 20. doi: 10.1164/rccm.201808-1476LE. [Epub ahead of print] No abstract available.

PMID:
30235006
13.

Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals.

Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, Ost DE, Punjabi NM, Schatz M, Smyth AR, Stewart PW, Suissa S, Adjei AA, Akdis CA, Azoulay É, Bakker J, Ballas ZK, Bardin PG, Barreiro E, Bellomo R, Bernstein JA, Brusasco V, Buchman TG, Chokroverty S, Collop NA, Crapo JD, Fitzgerald DA, Hale L, Hart N, Herth FJ, Iwashyna TJ, Jenkins G, Kolb M, Marks GB, Mazzone P, Moorman JR, Murphy TM, Noah TL, Reynolds P, Riemann D, Russell RE, Sheikh A, Sotgiu G, Swenson ER, Szczesniak R, Szymusiak R, Teboul JL, Vincent JL.

Ann Am Thorac Soc. 2019 Jan;16(1):22-28. doi: 10.1513/AnnalsATS.201808-564PS. No abstract available. Erratum in: Ann Am Thorac Soc. 2019 Feb;16(2):283.

PMID:
30230362
14.

Work environment risks for health care workers with cystic fibrosis.

Bell SC, Armstrong D, Harrington G, Jardine L, Divakaran R, Loff B, Middleton PG, McDonald T, Rowland K, Wishart M, Wood ME, Stuart RL.

Respirology. 2018 Dec;23(12):1190-1197. doi: 10.1111/resp.13404. Epub 2018 Sep 14.

PMID:
30215873
15.

Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention.

Bell SC, Elborn JS, Byrnes CA.

Respirology. 2018 Nov;23(11):1006-1022. doi: 10.1111/resp.13398. Epub 2018 Sep 11. Review.

16.

Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.

Martin LW, Robson CL, Watts AM, Gray AR, Wainwright CE, Bell SC, Ramsay KA, Kidd TJ, Reid DW, Brockway B, Lamont IL.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01789-18. doi: 10.1128/AAC.01789-18. Print 2018 Nov.

PMID:
30201819
17.

Differential expression of genes and receptors in monocytes from patients with cystic fibrosis.

Tarique AA, Sly PD, Cardenas DG, Luo L, Stow JL, Bell SC, Wainwright CE, Fantino E.

J Cyst Fibros. 2018 Aug 31. pii: S1569-1993(18)30744-6. doi: 10.1016/j.jcf.2018.07.012. [Epub ahead of print]

PMID:
30177416
18.

Whole genome sequencing reveals the emergence of a Pseudomonas aeruginosa shared strain sub-lineage among patients treated within a single cystic fibrosis centre.

Wee BA, Tai AS, Sherrard LJ, Ben Zakour NL, Hanks KR, Kidd TJ, Ramsay KA, Lamont I, Whiley DM, Bell SC, Beatson SA.

BMC Genomics. 2018 Aug 30;19(1):644. doi: 10.1186/s12864-018-5018-x.

19.

Lower airway microbiota for 'biomarker' measurements of cystic fibrosis disease progression?

Sherrard LJ, Bell SC.

Thorax. 2018 Nov;73(11):1001-1003. doi: 10.1136/thoraxjnl-2018-212165. Epub 2018 Aug 22. No abstract available.

PMID:
30135092
20.

Increased Numbers of Culturable Inhibitory Bacterial Taxa May Mitigate the Effects of Batrachochytrium dendrobatidis in Australian Wet Tropics Frogs.

Bell SC, Garland S, Alford RA.

Front Microbiol. 2018 Jul 18;9:1604. doi: 10.3389/fmicb.2018.01604. eCollection 2018.

21.

Face Masks Reduce the Release of Pseudomonas aeruginosa Cough Aerosols When Worn for Clinically Relevant Periods.

Stockwell RE, Wood ME, He C, Sherrard LJ, Ballard EL, Kidd TJ, Johnson GR, Knibbs LD, Morawska L, Bell SC; CF Cough Aerosol Group.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1339-1342. doi: 10.1164/rccm.201805-0823LE. No abstract available.

PMID:
30028634
22.

Transcriptomic analysis of longitudinal Burkholderia pseudomallei infecting the cystic fibrosis lung.

Price EP, Viberg LT, Kidd TJ, Bell SC, Currie BJ, Sarovich DS.

Microb Genom. 2018 Aug;4(8). doi: 10.1099/mgen.0.000194. Epub 2018 Jul 10.

23.

Anomalies in T Cell Function Are Associated With Individuals at Risk of Mycobacterium abscessus Complex Infection.

Lutzky VP, Ratnatunga CN, Smith DJ, Kupz A, Doolan DL, Reid DW, Thomson RM, Bell SC, Miles JJ.

Front Immunol. 2018 Jun 11;9:1319. doi: 10.3389/fimmu.2018.01319. eCollection 2018.

24.

Bronchiectasis: Yet another systemic disease?

Geake J, Bell SC.

Respirology. 2018 May 2. doi: 10.1111/resp.13322. [Epub ahead of print] No abstract available.

25.

Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei.

Wood ME, Stockwell RE, Johnson GR, Ramsay KA, Sherrard LJ, Kidd TJ, Cheney J, Ballard EL, O'Rourke P, Jabbour N, Wainwright CE, Knibbs LD, Sly PD, Morawska L, Bell SC.

Thorax. 2019 Jan;74(1):87-90. doi: 10.1136/thoraxjnl-2018-211567. Epub 2018 Apr 7.

PMID:
29627800
26.

Reef invertebrate viromics: diversity, host specificity and functional capacity.

Laffy PW, Wood-Charlson EM, Turaev D, Jutz S, Pascelli C, Botté ES, Bell SC, Peirce TE, Weynberg KD, van Oppen MJH, Rattei T, Webster NS.

Environ Microbiol. 2018 Mar 25. doi: 10.1111/1462-2920.14110. [Epub ahead of print]

PMID:
29575552
27.

ECFS best practice guidelines: the 2018 revision.

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P.

J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. Review.

28.

Biomarkers: Their Role in CFTR Modulator Therapies from Early Development to the Clinic.

Bell SC, Wood ME.

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1375-1376. doi: 10.1164/rccm.201801-0177ED. No abstract available.

PMID:
29406823
29.

The experience of men and women with cystic fibrosis who have become a parent: A qualitative study.

Jessup M, Li A, Fulbrook P, Bell SC.

J Clin Nurs. 2018 Apr;27(7-8):1702-1712. doi: 10.1111/jocn.14229. Epub 2018 Mar 9.

PMID:
29266748
30.

Learning's from the Editors Desk - 2017.

Bell SC, Castellani C, Flume PA.

J Cyst Fibros. 2017 Nov;16(6):645-646. doi: 10.1016/j.jcf.2017.10.001. No abstract available.

PMID:
29150008
31.

Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Tai AS, Sherrard LJ, Kidd TJ, Ramsay KA, Buckley C, Syrmis M, Grimwood K, Bell SC, Whiley DM.

BMC Pulm Med. 2017 Nov 2;17(1):138. doi: 10.1186/s12890-017-0482-7.

32.

Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of Pseudomonas aeruginosa in People with Cystic Fibrosis.

Wood ME, Stockwell RE, Johnson GR, Ramsay KA, Sherrard LJ, Jabbour N, Ballard E, O'Rourke P, Kidd TJ, Wainwright CE, Knibbs LD, Sly PD, Morawska L, Bell SC.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):348-355. doi: 10.1164/rccm.201707-1457OC.

PMID:
28930641
33.

Early Intervention of Cystic Fibrosis Pulmonary Exacerbations Based on Home Monitoring. eICE through the Looking Glass.

Bell SC.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1090-1092. doi: 10.1164/rccm.201706-1207ED. No abstract available.

PMID:
28696781
34.

The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis.

Chin M, Aaron SD, Bell SC.

Presse Med. 2017 Jun;46(6 Pt 2):e139-e164. doi: 10.1016/j.lpm.2016.11.030. Epub 2017 May 31. Review.

PMID:
28576636
35.

Tropical Australia is a potential reservoir of non-tuberculous mycobacteria in cystic fibrosis.

Sherrard LJ, Tay GT, Butler CA, Wood ME, Yerkovich S, Ramsay KA, Reid DW, Moore VL, Kidd TJ, Bell SC.

Eur Respir J. 2017 May 11;49(5). pii: 1700046. doi: 10.1183/13993003.00046-2017. Print 2017 May. No abstract available.

36.

CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis.

Tarique AA, Sly PD, Holt PG, Bosco A, Ware RS, Logan J, Bell SC, Wainwright CE, Fantino E.

J Cyst Fibros. 2017 Jul;16(4):475-482. doi: 10.1016/j.jcf.2017.03.011. Epub 2017 Apr 17.

PMID:
28428011
37.

Within-Host Evolution of Burkholderia pseudomallei during Chronic Infection of Seven Australasian Cystic Fibrosis Patients.

Viberg LT, Sarovich DS, Kidd TJ, Geake JB, Bell SC, Currie BJ, Price EP.

MBio. 2017 Apr 11;8(2). pii: e00356-17. doi: 10.1128/mBio.00356-17.

38.

Sources and dynamics of fluorescent particles in hospitals.

Pereira ML, Knibbs LD, He C, Grzybowski P, Johnson GR, Huffman JA, Bell SC, Wainwright CE, Matte DL, Dominski FH, Andrade A, Morawska L.

Indoor Air. 2017 Sep;27(5):988-1000. doi: 10.1111/ina.12380. Epub 2017 May 5.

PMID:
28303606
39.

Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis.

Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson SA, Bell SC.

PLoS One. 2017 Mar 8;12(3):e0172179. doi: 10.1371/journal.pone.0172179. eCollection 2017. Erratum in: PLoS One. 2019 Jan 14;14(1):e0210929.

40.

Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?

Bell SC, Flume PA.

Thorax. 2017 Apr;72(4):297-299. doi: 10.1136/thoraxjnl-2016-209605. Epub 2017 Jan 11. No abstract available.

PMID:
28077615
41.

Life history linked to immune investment in developing amphibians.

Woodhams DC, Bell SC, Bigler L, Caprioli RM, Chaurand P, Lam BA, Reinert LK, Stalder U, Vazquez VM, Schliep K, Hertz A, Rollins-Smith LA.

Conserv Physiol. 2016 Aug 26;4(1):cow025. eCollection 2016.

42.

Effect of Nerve Stimulation Use on the Success Rate of Ultrasound-Guided Subsartorial Saphenous Nerve Block: A Randomized Controlled Trial.

Montgomery SH, Shamji CM, Yi GS, Yarnold CH, Head SJ, Bell SC, Schwarz SK.

Reg Anesth Pain Med. 2017 Jan/Feb;42(1):25-31. doi: 10.1097/AAP.0000000000000522.

PMID:
27902645
43.

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.

Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP; VX09-809-102 Study Group.

Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC.

44.

Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Verma D, Hill E, Drijkoningen J, Gilligan P, Esther CR, Noone PG, Giddings O, Bell SC, Thomson R, Wainwright CE, Coulter C, Pandey S, Wood ME, Stockwell RE, Ramsay KA, Sherrard LJ, Kidd TJ, Jabbour N, Johnson GR, Knibbs LD, Morawska L, Sly PD, Jones A, Bilton D, Laurenson I, Ruddy M, Bourke S, Bowler IC, Chapman SJ, Clayton A, Cullen M, Daniels T, Dempsey O, Denton M, Desai M, Drew RJ, Edenborough F, Evans J, Folb J, Humphrey H, Isalska B, Jensen-Fangel S, Jönsson B, Jones AM, Katzenstein TL, Lillebaek T, MacGregor G, Mayell S, Millar M, Modha D, Nash EF, O'Brien C, O'Brien D, Ohri C, Pao CS, Peckham D, Perrin F, Perry A, Pressler T, Prtak L, Qvist T, Robb A, Rodgers H, Schaffer K, Shafi N, van Ingen J, Walshaw M, Watson D, West N, Whitehouse J, Haworth CS, Harris SR, Ordway D, Parkhill J, Floto RA.

Science. 2016 Nov 11;354(6313):751-757. doi: 10.1126/science.aaf8156.

45.

Implication of LRRC4C and DPP6 in neurodevelopmental disorders.

Maussion G, Cruceanu C, Rosenfeld JA, Bell SC, Jollant F, Szatkiewicz J, Collins RL, Hanscom C, Kolobova I, de Champfleur NM, Blumenthal I, Chiang C, Ota V, Hultman C, O'Dushlaine C, McCarroll S, Alda M, Jacquemont S, Ordulu Z, Marshall CR, Carter MT, Shaffer LG, Sklar P, Girirajan S, Morton CC, Gusella JF, Turecki G, Stavropoulos DJ, Sullivan PF, Scherer SW, Talkowski ME, Ernst C.

Am J Med Genet A. 2017 Feb;173(2):395-406. doi: 10.1002/ajmg.a.38021. Epub 2016 Oct 19.

46.

The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.

Ramsay KA, Sandhu H, Geake JB, Ballard E, O'Rourke P, Wainwright CE, Reid DW, Kidd TJ, Bell SC.

J Cyst Fibros. 2017 Jan;16(1):70-77. doi: 10.1016/j.jcf.2016.07.010. Epub 2016 Aug 8.

47.

Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey.

Madge S, Bell SC, Burgel PR, De Rijcke K, Blasi F, Elborn JS; ERS/ECFS task force: The provision of care for adults with cystic fibrosis in Europe.

J Cyst Fibros. 2017 Jan;16(1):85-88. doi: 10.1016/j.jcf.2016.07.001. Epub 2016 Jul 26.

48.

The role of anaerobic bacteria in the cystic fibrosis airway.

Sherrard LJ, Bell SC, Tunney MM.

Curr Opin Pulm Med. 2016 Nov;22(6):637-43. doi: 10.1097/MCP.0000000000000299. Review.

PMID:
27455453
49.

A Novel Method and Its Application to Measuring Pathogen Decay in Bioaerosols from Patients with Respiratory Disease.

Johnson GR, Knibbs LD, Kidd TJ, Wainwright CE, Wood ME, Ramsay KA, Bell SC, Morawska L.

PLoS One. 2016 Jul 7;11(7):e0158763. doi: 10.1371/journal.pone.0158763. eCollection 2016.

50.

The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

Stephenson AL, Bell SC.

Ann Am Thorac Soc. 2016 Jul;13(7):1014-5. doi: 10.1513/AnnalsATS.201604-250ED. No abstract available.

PMID:
27388403

Supplemental Content

Support Center